| 1. |
- Sediva, A, et al.
(författare)
-
Europe Immunoglobulin Map
- 2014
-
Ingår i: JOURNAL OF CLINICAL IMMUNOLOGY. - : Oxford University Press (OUP). - 0271-9142. ; 178178 Suppl 1, s. 141-143
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Edman, L, et al.
(författare)
-
Health-related quality of life, symptom distress and sense of coherence in adult survivors of allogeneic stem-cell transplantation
- 2001
-
Ingår i: European Journal of Cancer Care. - Oxford : Hindawi Limited. - 0961-5423 .- 1365-2354. ; 10:2, s. 124-130
-
Tidskriftsartikel (refereegranskat)abstract
- This is the first Swedish study to evaluate the health-related quality of life and sense of coherence in adult survivors of allogeneic, haematopoietic stem cell transplantation (HSCT). Twenty-five recipients completed three questionnaires 2-4 years after the transplantation. The questionnaires used were the Sickness Impact Profile (SIP), the Symptom Frequency Intensity and Distress (SFID-BMT) scale and the Sense of Coherence (SOC) scale measuring subjective functional status, symptom distress and coping ability. Impairments in functional status were found, as compared with a population norm. The most common impairments were found in the areas of social interaction and sleep and rest. Eye problems, dry mouth, cough, sexual problems, tiredness, anxiety and changes of taste were symptoms reported by more than half of the patients. Despite impaired functioning and a high incidence of symptoms, the general health was described as quite good or excellent by 80% (n = 20) of the patients. The majority (20/22) had also been able to return to work or to attend school. No difference in the sense of coherence was seen, as compared with the population norm. Functional impairments were significantly correlated to a lower degree of sense of coherence.
|
|
| 11. |
|
|
| 12. |
|
|
| 13. |
- GARDULF, A, et al.
(författare)
-
A comparison of the patient-borne costs of therapy with gamma globulin given at the hospital or at home
- 1995
-
Ingår i: International journal of technology assessment in health care. - : Cambridge University Press (CUP). - 0266-4623 .- 1471-6348. ; 11:2, s. 345-353
-
Tidskriftsartikel (refereegranskat)abstract
- The major aim of this study was to estimate and compare the patient-borne costs of lifelong subcutaneous gamma globulin therapy at the hospital and at home. Thirty patients were included and the data were collected with a questionnaire. The introduction of self-therapy at home reduced the total yearly costs by approximately 50% and the out-of-pocket expenses for the palients by 85%.
|
|
| 14. |
|
|
| 15. |
- Gardulf, A
(författare)
-
Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®)
- 2016
-
Ingår i: Immunotherapy. - : Future Medicine Ltd. - 1750-7448 .- 1750-743X. ; 8:5, s. 633-647
-
Tidskriftsartikel (refereegranskat)abstract
- Treatment for primary and secondary immunodeficiency disorders focuses on prevention and management of infections, using immunoglobulin G (IgG) replacement therapy with regular intravenous or subcutaneous IgG (SCIG) infusions. SCIG therapy has many advantages including improved efficacy and tolerability, enhanced patient satisfaction and lower costs. A number of SCIG preparations are available, including Gammanorm®(Octapharma AG), a ready-to-use 16.5% liquid preparation of IgG, with low viscosity, well suited to self-administration and a long history of use. Clinical experience with Gammanorm has shown that it is effective and well tolerated in children and adults, including pregnant women, for primary and secondary immunodeficiency disorders. Recent data also suggest SCIG may have a role in the treatment of certain immune-mediated conditions.
|
|
| 16. |
|
|
| 17. |
|
|
| 18. |
|
|
| 19. |
|
|
| 20. |
|
|
| 21. |
|
|
| 22. |
|
|
| 23. |
|
|
| 24. |
|
|
| 25. |
|
|
